CASEY STEPHENSON: Open Payments
NPI 1922782614 · SHEFFIELD, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$407 in 29 payments from 9 companies in 2025. Trend: 2023 $39 · 2024 $405 · 2025 $407
Food & beverage: $407
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 17 | $163 |
| Vanda Pharmaceuticals Inc. | 2 | $57 |
| Xeris Pharmaceuticals, Inc. | 2 | $45 |
| AstraZeneca Pharmaceuticals LP | 2 | $42 |
| Amgen Inc. | 2 | $28 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $26 |
| PFIZER INC. | 1 | $19 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $14 |
| Exact Sciences Corporation | 1 | $14 |
Products named: QULIPTA, FANAPT, VRAYLAR, UBRELVY, RECORLEV, FARXIGA, OTEZLA, Kerendia.
Industry payments across AL — which companies pay providers there.
